Healthcare Services

Lupus Nephritis Market Revenue Growth Expected to Reach $2.98 Billion by 2030 with 7.4% CAGR

April 2, 2026April 15, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Expected Market Size Of The Lupus Nephritis Market From 2026 To 2030?

The lupus nephritis market has experienced significant expansion in recent years. It is anticipated to grow from $2.08 billion in 2025 to $2.24 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.7%. This growth observed in the past can be attributed to factors such as the increasing prevalence of systemic lupus erythematosus, improved kidney biopsy and diagnostic practices, the widespread use of corticosteroids in treatment, the expansion of hospital-based nephrology care, and increased awareness of autoimmune kidney diseases.

The market for lupus nephritis is projected to experience substantial expansion in the coming years. By 2030, this market is anticipated to reach a value of $2.98 billion, demonstrating a compound annual growth rate (CAGR) of 7.4%. This projected growth is linked to several factors, including increased investment in the development of biologic drugs, a greater emphasis on early intervention to avert kidney failure, the wider acceptance of combination therapy treatments, the proliferation of specialized nephrology clinics, and increased expenditure on managing autoimmune diseases within healthcare. Key developments expected during this period involve a heightened focus on timely diagnosis and monitoring of the disease, the increasing use of immunosuppressive and biologic therapies, a greater drive towards tailored treatment strategies, the broadening of long-term disease management plans, and an improved understanding of kidney complications arising from autoimmune conditions.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22044&type=smp

What Key Drivers Are Influencing The Growth Of The Lupus Nephritis Market?

The increasing occurrence of genetic predisposition is projected to drive the expansion of the lupus nephritis market in the foreseeable future. Genetic predisposition refers to an individual’s inherited genetic traits that heighten their probability of developing particular diseases or conditions. The rising incidence of genetic predisposition results from factors such as inheritance, environmental influences, and mutations in specific genes. This growing prevalence plays a vital role in the manifestation of lupus nephritis, underscoring the significance of inherited genetic factors in autoimmune diseases, particularly those that affect kidney function. For instance, in October 2024, according to the Cystic Fibrosis Trust, a UK-based national charity, the UK CF Registry recorded 11,148 registered patients in 2022, which increased to 11,318 in 2024, reflecting a 1.52% increase in individuals with cystic fibrosis (CF). Consequently, the increasing prevalence of genetic predisposition is stimulating the growth of the lupus nephritis market.

Which Segments Are Included In The Analysis Of The Lupus Nephritis Market?

The lupus nephritis market covered in this report is segmented –

1) By Stage: Class 1, Class 2, Class 3, Other Stages

2) By Drug Class: Immunosuppressive Drugs, Corticosteroids, Biological Agents, Antimalarial Drugs

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

5) By End-User: Hospitals, Specialty Clinics, Other End-Users

Subsegments:

1) By Class 1: Asymptomatic Cases, Mild Proteinuria, Incidental Diagnosis

2) By Class 2: Mild Hematuria, Low-Grade Proteinuria, Minimal Immune Complex Deposition

3) By Class 3: Active Lesions, Chronic Sclerotic Lesions, Crescent Formation

4) By Other Stages: Class 4 (Diffuse Lupus Nephritis), Class 5 (Membranous Lupus Nephritis), Class 6 (Advanced Sclerotic Lupus Nephritis)

How Are Trends Transforming The Lupus Nephritis Market Landscape?

Leading companies active in the lupus nephritis market are directing their efforts toward developing sophisticated second-generation calcineurin inhibitors, with the goal of enhancing treatment efficacy and improving long-term kidney outcomes for patients. These second-generation calcineurin inhibitors are utilized in lupus nephritis to alleviate inflammation and prevent kidney damage by moderating immune responses. For instance, in September 2024, Aurinia Pharmaceuticals Inc., a Canada-based commercial-stage biopharmaceutical company, announced that the Japanese Ministry of Health, Labour, and Welfare approved LUPKYNIS (voclosporin) for the treatment of lupus nephritis. This authorization permits voclosporin to be administered in conjunction with mycophenolate mofetil (MMF), based on findings from the AURORA Clinical Program, which confirmed its safety and efficacy. The approval signifies a major step forward in expanding therapeutic alternatives for lupus nephritis patients in Japan, leading to improved disease management and patient results.

Which Key Industry Participants Are Active In The Lupus Nephritis Market?

Major companies operating in the lupus nephritis market are F Hoffmann La Roche Ltd, Bristol Myers Squibb, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, AstraZeneca PLC, Pfizer Inc, Johnson and Johnson, Merck and Co Inc, Sanofi, AbbVie Inc, Bayer AG, Amgen Inc, UCB SA, Otsuka Pharmaceutical Co Ltd, Aurinia Pharmaceuticals Inc, RemeGen Co Ltd, Kezar Life Sciences, Equillium Inc, Kyverna Therapeutics Inc, Biogen Inc

Read the full lupus nephritis market report here:

https://www.thebusinessresearchcompany.com/report/lupus-nephritis-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Lupus Nephritis Market?

Asia-Pacific was the largest region in the lupus nephritis market in 2025. The regions covered in the lupus nephritis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Lupus Nephritis Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=22044&type=smp

Browse Through More Reports Similar to the Global Lupus Nephritis Market 2026, By The Business Research Company

Cutaneous Lupus Erythematosus Global Market Report

https://www.thebusinessresearchcompany.com/report/cutaneous-lupus-erythematosus-global-market-report

Lupus Therapeutics Global Market Report

https://www.thebusinessresearchcompany.com/report/lupus-therapeutics-global-market-report

Kidney Disease Global Market Report

https://www.thebusinessresearchcompany.com/report/kidney-disease-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795